The Cancer Therapeutics Program brings together clinical investigators who work together with basic and translational scientists to advance promising therapeutic options to patients in clinical trials. Program meetings are held every two weeks throughout the year. There is a robust portfolio of early phase clinical trials led by investigators through the Brown University Oncology Group (BrUOG), Lifespan Cancer Institute and Women's and Infants Hospital. The Program has depth of expertise in disease-based adult and pediatric oncology, pathology, and clinical investigations. The early phase experimental therapeutics effort has a strong focus on cell death pathways and immunotherapy.
Program members interact with the Cancer Biology Program to bring forward novel biomarkers as well as therapeutics into early phase clinical trials. Efforts to translate novel concepts are supported by the Translational Research Disease Groups (TRDGs), which are additional cancer disease-based group meetings that occur in parallel to the Cancer Therapeutics Program Meetings. Each of the 11 disease-based TRDGs meets every 2-3 months, with emerging projects being presented at the Cancer Therapeutics Program meetings.
-
Benedito Carneiro, MD
Group Leader (Cancer Therapeutics); TRDG Leader (GU Cancer); Director, Phase I Clinical Research Program, Cell death targeted therapeutics, Immunotherapy
-
Howard Safran, MD
Group Leader (Cancer Therapeutics); TRDG Leader and Facilitator, Medical Director, BrUOG, Chief, Hematology/Oncology, Brown and Lifespan, GI and brain cancer therapeutics, Experimental therapeutics
Group Members
Stephanie Graff, MD
Director of the Breast Oncology Program at Lifespan Cancer Institute, and co-leader of the Breast Cancer Translational Research Disease Group.
Shougang Zhuang, MD, PhD
Professor of Medicine (Research)
Ting Zhao, MD
Associate Professor of Surgery
Tom DiPetrillo, MD
TRDG Leader (Thoracic Malignancies and GU Cancer); Radiation Oncology, IMRT, HDR, Brachytherapy
Don Dizon, MD
TRDG Leader (GYN Cancers), Director, Women’s Cancers, Lifespan, GYN cancer therapeutics
Wafik El-Deiry, MD, PhD, FACP
Director, Joint Program in Cancer Biology; TRDG Leader and Facilitator, Drug Discovery, Signaling, drug resistance, TRAIL, p53, p21, ONC201
Mary Anne Fenton, MD
TRDG Leader (Breast Cancer); Clinical Director, Breast Medical Oncology, RIH, Director of Quality, LCI
Sheldon Holder, MD, PhD
Assistant Professor of Pathology and Laboratory Medicine | Medical Oncologist | Physician Scientist
Suchitra Kamle, PhD
Molecular Microbiology and Immunology, antibody engineering
John Reagan, MD
TRDG Co-Leader (Hematological Malignancies), Hematological malignancies Immune therapies
Ilyas Sahin, MD
Assistant Professor, Hematology Oncology, Cancer immunotherapy, Immunotherapy resistance
Attila A Seyhan, PhD
Director of Translational Oncology Operations, Joint Program in Cancer Biology, Brown University and Lifespan Cancer Institute; Core Director of Translational Oncology; Adjunct Associate Professor, Tumor metabolism and RNA processing
Robert Sobol, PhD
Professor of Pathology and Laboratory Medicine, Cancer DNA damage and repair, DNA replication, Environmental toxicology, mouse models, NAD (Coenzyme) , PARP
David Wazer, MD
TRDG Member, Director, LCI, Radiation Oncology, Brachytherapy, Proton beam, Breast, skin, GI, lung cancer
Lei Wei, MD
Associate Professor of Orthopaedics (Research)